Mi az ára AstraZeneca PLC (AZN)

AstraZeneca PLC (AZN) ára $169.98

Mi a AstraZeneca PLC (AZN piaci tőkésítése)

AstraZeneca PLC piaci tőkésítése (AZN) $2.64B

AstraZeneca PLC (AZN) Működési Eredményhányad

AstraZeneca PLC operates as a biopharmaceutical company, specializing in the discovery, development, manufacturing, and commercialization of prescription medications. Its comprehensive portfolio addresses diverse therapeutic areas. In oncology, key marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. For cardiovascular, renal, and metabolism diseases, the company offers treatments such as Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR. Respiratory and immunology conditions are targeted by products like Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris. Additionally, rare diseases are treated with Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris. The company's product offerings also extend to Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for influenza; Seroquel IR/Seroquel XR for schizophrenia and bipolar disorder; Nexium and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for COVID-19. AstraZeneca serves primary and specialty care physicians globally, leveraging a network of distributors and local representative offices across the United Kingdom, the rest of Europe, the Americas, Asia, Africa, and Australasia. Strategic collaboration forms a vital component of its operations. Partnerships include an agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG for the development and commercialization of NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for transthyretin amyloidosis; Proteros Biostructures GmbH for the joint discovery of novel small molecules targeting hematological cancers; and Sierra Oncology, Inc. for the development and commercialization of AZD5153. Initially incorporated in 1992 as Zeneca Group PLC, the company adopted its current name, AstraZeneca PLC, in April 1999. It is headquartered in Cambridge, United Kingdom.

Év	Működési árrés	Változtassa meg
2026 (TTM)	22.69%	-4.06%
2024	23.65%	15.14%
2023	20.54%	80.02%
2022	11.41%	50.73%
2021	7.57%	-55.42%
2020	16.98%	47.52%
2019	11.51%	38.51%
2018	8.31%	-46.21%
2017	15.45%	-0.26%
2016	15.49%	6.90%
2015	14.49%	3.95%
2014	13.94%	-41.77%
2013	23.94%	-24.38%
2012	31.66%	-12.49%
2011	36.18%	-4.69%
2010	37.96%	8.15%
2009	35.10%	11.39%
2008	31.51%	11.78%
2007	28.19%	-3.85%
2006	29.32%	9.73%
2005	26.72%	31.24%
2004	20.36%	-6.65%
2003	21.81%	-10.69%
2002	24.42%	1.79%
2001	23.99%	18.59%
2000	20.23%	0.00%

Év

Működési árrés

Változtassa meg

2026 (TTM)

22.69%

-4.06%

2024

23.65%

15.14%

2023

20.54%

80.02%

2022

11.41%

50.73%

2021

7.57%

-55.42%

2020

16.98%

47.52%

2019

11.51%

38.51%

2018

8.31%

-46.21%

2017

15.45%

-0.26%

2016

15.49%

6.90%

2015

14.49%

3.95%

2014

13.94%

-41.77%

2013

23.94%

-24.38%

2012

31.66%

-12.49%

2011

36.18%

-4.69%

2010

37.96%

8.15%

2009

35.10%

11.39%

2008

31.51%

11.78%

2007

28.19%

-3.85%

2006

29.32%

9.73%

2005

26.72%

31.24%

2004

20.36%

-6.65%

2003

21.81%

-10.69%

2002

24.42%

1.79%

2001

23.99%

18.59%

2000

20.23%

0.00%

Vállalat	Működési árrés	Működési árrés különbség	Ország
Eli Lilly and Company LLY.US	43.92%	-98.06%	US
Johnson & Johnson JNJ.US	26.81%	-98.82%	US
AbbVie Inc. ABBV.US	29.32%	-98.71%	US
Roche Holding AG RO.SW	26.59%	-98.83%	CH
Merck & Co., Inc. MRK.US	16.65%	-99.27%	US

Vállalat

Működési árrés

Működési árrés különbség

Ország